Aethlon Medical, Inc. — Form 8-K Summary
Business context and period: The filing reports results of Aethlon Medical’s virtual annual meeting held October 1, 2026. It is a corporate-governance and capital-authorization filing, not a periodic financial report.
Key financial and capital metrics
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or operating-performance figures. It does not provide a clear financial outlook.
- As of the August 10, 2026 record date, the company reported 711,136 common shares issued and outstanding. Approximately 56.21% of shares entitled to vote were represented at the meeting.
- Stockholders approved increasing the common shares authorized under the 2020 Equity Incentive Plan by 100,000 shares. The amendment became effective October 1, 2026.
- Stockholders approved increasing authorized common shares from 20,000,000 to 200,000,000, and authorizing 20,000,000 shares of preferred stock. The filing does not state that these authorized shares have been issued.
- Stockholders approved issuance of up to 1,126,602 common shares upon exercise of warrants issued in the July 2026 offering.
- Stockholders also approved Nasdaq-related proposals covering potential share or convertible-security issuance in future private financings and future warrant-exercise inducement transactions. The filing does not specify the size or terms of those future transactions.
Meeting results and changes
- Stockholders elected five directors: Edward G. Broenniman, James B. Frakes, Nicolas Gikakis, Angela Rossetti, and Chetan S. Shah, MD.
- Stockholders ratified Haskell & White LLP as independent auditor for the fiscal year ending March 31, 2027.
- Executive compensation was approved on an advisory basis.
- The proposal authorizing adjournment to solicit additional proxies passed, but the meeting chair did not adjourn the meeting.
- This filing does not provide prior-period financial results for comparison.
Outlook, risks, and unusual items
The approvals expand the company’s authorized equity capacity and permit specified potential securities issuances, which could result in dilution if shares or convertible securities are issued. The filing provides no guidance, management discussion of operating prospects, or financial contingencies. Further details of the equity-plan amendment are incorporated from the August 21, 2026 proxy statement and the attached amended plan.
Important facts for investors to verify
- Review the proxy statement and amended equity plan for plan terms and the effect of the additional 100,000 plan shares.
- Confirm the terms and potential share impact of the July 2026 warrants, including the approved issuance of up to 1,126,602 shares.
- Monitor any future private financings or warrant-inducement transactions authorized by the votes, as their terms and dilution are not specified here.
- Review subsequent filings for whether the increased common and preferred share authorizations are used or preferred-stock terms are established.